Abstract:What is known and objective: Rheumatoid arthritis is an autoimmune disorder characterized by persistent synovitis and systemic inflammation. Genetic factors account for approximately 50% of cases of rheumatoid arthritis and environmental factors include smoking. Urinary incontinence may occur as a medication adverse effect. We present the first report of a case of hydroxychloroquine-induced urinary incontinence in rheumatoid arthritis. Details of the case: A 71-year-old female with a history of rheumatoid arthritis developed urinary incontinence as an adverse drug reaction to hydroxychloroquine administered at therapeutic doses. Urinary incontinence remitted with drug withdrawal and reappeared on rechallenge. The Naranjo's algorithm indicated that hydroxychloroquine was a probable cause of this adverse drug reaction. The likely mechanism of this adverse drug is a direct action of the quinolone on the urinary system. What is new and conclusion: This is the first report of hydroxychloroquine-induced urinary incontinence. The absence of previous reports suggest that the drug rarely causes this adverse effect. Methotrexate is most often used as first-line treatment, and several other drugs are now available to act as Disease-Modifying Antirheumatic Drugs (DMARDs). These drugs may be used alone or combined with methotrexate, most often to increase efficacy and reduce toxicity. The introduction of new biological agents, such as abatacept, rituximab, tocilizumab and inhibitors of tumour necrosis factor, has opened new therapeutic perspectives but are restricted by high costs and risk of infections. Thus, antimalarial drugs, especially the quinolones chloroquine (CQ) and hydroxychloroquine (HCQ), are still in use, and the latter is very efficacious. An advantage of HCQ is its low toxicity compared with other antimalarial drugs. Common side-effects of HCQ and the other antimalarial drugs include gastrointestinal effects such as nausea and vomiting, as well as skin rashes and headache, whereas their most common and severe side-effect is retinopathy. No case of urinopathy has been reported previously with HCQ.

Chloroquine -induced hair depigmentation

Oral Pigmentation Caused By Chronic Use Of Chloroquine: Report Of Two Cases.

Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis

A case report on hydroquinone induced exogenous ochronosis

Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors

Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function

Hydroxychloroquine-induced hyperpigmentation of the skin and bull's-eye maculopathy in rheumatic patients: a case report and literature review

Drug-Induced Pigmentation: A Review

Diffuse Facial Leukoderma Secondary to Localized Use of Hydroquinone

Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature

Pigmented oral mucosa due to quinacrine

Atypical Dyschromia in Skin of Color

A case of urinary incontinence by hydroxychloroquine in a geriatric patient

Hydroxychloroquine in systemic lupus erythematosus and psychosis. A case report

Nail Discoloration Following the Chronic Use of Skin-Depigmenting Creams

Adverse cutaneous reaction to hydroxychloroquine in a patient with anti-SAE-1-positive dermatomyositis and a history of diffuse large B-cell lymphoma

Hydroxychloroquine-induced podocytopathy mimicking Fabry disease

Reversible Hyperpigmentation of Skin and Nails With White Hair due to Vitamin B12 Deficiency

Primary Cutaneous Marginal Zone Lymphoma following Repeated Inflammation Caused by Hair Dyeing

Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report

Disseminated superficial actinic porokeratosis following hydroxyurea treatment: A case report